What “compounded” means for semaglutide and tirzepatide in 2026

Compounding is neither a universal substitute for an approved medication nor proof that a product is unsafe. It is governed by federal and state requirements, and individual facts matter. Patients should expect precise explanations about the active ingredient, pharmacy, concentration, dose units, storage, and follow-up.

This guide reflects public FDA information available as of August 22, 2026. It is educational, not legal advice.

What is a compounded drug?

A compounded drug is prepared by combining, mixing, or altering ingredients for a clinical circumstance. It can serve an individual patient when an FDA-approved product cannot meet that patient’s medical need, or when an approved product is not commercially available. That does not mean every requested variation is permitted or justified. [1]

The most important distinction is review. FDA-approved drugs go through the agency’s premarket review for safety, effectiveness, and quality. Compounded drugs do not. FDA does not review a compounded drug for those qualities before it is marketed. [3]

That is why “compounded semaglutide” should never be shortened to “generic Ozempic” or “compounded Wegovy.” Semaglutide is the active ingredient in Ozempic and Wegovy. Tirzepatide is the active ingredient in Mounjaro and Zepbound. A compounded product is not affiliated with, endorsed by, or a substitute for any of those brands.

Why did GLP-1 compounding expand during shortages?

Federal law places limits on compounding products that are essentially copies of commercially available drugs. Drug shortages can change how some of those limits apply because an approved product may not be commercially available during a shortage.

During the national shortages of semaglutide and tirzepatide injection products, applicable policies allowed more room to prepare certain products. That period shaped language still circulating online, but it does not settle what is allowed now.

A prescription alone does not create a blanket exception, and prior shortage availability does not establish that the same activity can continue indefinitely.

What changed after the shortages ended?

As of August 22, 2026, semaglutide and tirzepatide were not on FDA’s drug-shortage list. In an April 1, 2026 policy clarification, FDA also stated that neither substance was on the list of bulk drug substances that 503B outsourcing facilities may use for compounding at that time. [1]

FDA explained that, under section 503A, a state-licensed pharmacy or physician cannot compound regularly or in inordinate amounts a drug product that is essentially a copy of a commercially available drug. A limited amount may be possible when the prescriber determines that a change produces a significant difference for an identified individual patient, but whether that standard is met is fact-specific. [1]

On April 30, 2026, FDA announced a proposal not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list after finding no clinical need for outsourcing facilities to compound them from bulk drug substances. [2] FDA later extended the public-comment period through July 30, 2026. As of August 22, 2026, that comment period had closed and FDA had not posted a final determination in its compounding policy materials. [5] A proposal is not a final determination, so the procedural status must be checked again before later reliance.

Shortage-era availability is not standing permission. A patient should not be told that a particular prescription is lawful without review of current facts.

What do 503A and 503B mean?

The numbers refer to sections of the Federal Food, Drug, and Cosmetic Act that describe different compounding pathways.

Section 503A generally concerns patient-specific compounding by a state-licensed pharmacy or a licensed physician when statutory conditions are met. The relationship to an identified individual patient and a valid prescription is central. State pharmacy and professional rules also apply.

Section 503B concerns outsourcing facilities that voluntarily register with FDA and meet a different set of federal conditions. These facilities may compound certain sterile drugs for healthcare settings, but registration does not make their compounded products FDA-approved. The bulk substances they may use are also restricted.

These are not quality grades. Both pathways involve compounded drugs that are not FDA-approved. Their operational, inspection, reporting, prescription, and distribution rules differ.

When might an individual clinical difference matter?

FDA recognizes that a compounded drug may be appropriate when an FDA-approved drug cannot meet an individual patient’s medical need. [1] That is a clinical statement, not an automatic loophole.

Under 503A, the federal framework for an essentially-copy analysis can consider whether a prescriber determines that a compounded change produces a significant difference for an identified patient. The determination should be tied to the patient and the actual formulation. It should not be a marketing phrase applied to everyone.

Patients should ask why a compounded preparation is being considered and how the decision relates to their clinical circumstances. The pharmacy should accurately identify what it dispenses. If the explanation is vague, brand-based, or presented as a universal workaround, ask for clarity.

What should you ask about a compounded GLP-1 product?

Before using a product, ask for details in writing:

1. What is the legal name and location of the dispensing pharmacy?
2. What is the exact active ingredient?
3. What is the concentration, expressed clearly per milliliter or other stated volume?
4. What dose was prescribed, and how does that dose translate into syringe or device units?
5. How should the medication be stored, and what is its beyond-use date?
6. What should the product and label look like when it arrives?
7. Who should you contact about dosing, side effects, temperature exposure, damage, or a suspected quality problem?
8. Why is a compounded preparation being considered for your individual care?

Verify the pharmacy through the relevant state board of pharmacy. FDA registration can also be checked for a facility that represents itself as a 503B outsourcing facility, but registration should not be described as FDA approval of the pharmacy or its products.

Why do salt forms and dosing units matter?

FDA has specifically warned about products made with semaglutide sodium or semaglutide acetate. These salt forms are different active ingredients from semaglutide used in the FDA-approved drugs. FDA says it is unaware of a lawful basis for using those salts in compounding. [3]

Ask for the exact active ingredient rather than accepting “semaglutide” as a complete answer. The label and prescription should also make the concentration and directions understandable.

Dosing units matter because compounded products may be supplied in multi-dose vials at different concentrations. A dose expressed in milligrams is not the same as a volume in milliliters or a marking in syringe units. FDA has received reports of dosing errors involving compounded injectable semaglutide, including errors linked to patients measuring the wrong amount and confusion across concentrations. [3]

Do not convert a dose from one product or vial to another on your own. If the prescription, vial, syringe, and instructions do not align clearly, stop and contact the prescribing team or dispensing pharmacy before injecting.

What should marketing never imply?

Marketing should not erase the distinction between compounded and approved drugs. Pause if a site claims or strongly implies that:

• the compounded product is generic Ozempic, Wegovy, Mounjaro, or Zepbound
• the compounded product has the same safety and effectiveness as a brand product
• the pharmacy or product is FDA-approved or FDA-licensed
• a prescription automatically makes the compounding lawful
• shortage-era mass availability continues unchanged
• a research-use product is appropriate for human treatment

FDA’s June 8, 2026 warning letter to a telehealth company illustrates concerns with “FDA licensed” phrasing and claims that may create an impression of approval or equivalence. [4] A warning letter concerns the facts FDA identified in that case. It is still a useful reminder to read exact claims carefully.

Accurate language is narrower: the product is compounded, is not FDA-approved, and may be prescribed only when a licensed provider determines it is clinically appropriate under current conditions.

How should a patient decide?

Start with the clinical reason, not the brand association. Ask what approved options exist, why a compounded preparation is being considered, and which current rules apply. Confirm the pharmacy, active ingredient, concentration, directions, and route for questions.

Then evaluate the care relationship. A licensed provider should review your history and other medications, explain material risks and alternatives, and remain available for follow-up. Weight-loss medication supports, and does not replace, diet and exercise. Individual results vary.

For a separate comparison of the two active ingredients, read tirzepatide vs semaglutide. General treatment information is available on the weight-loss hub.

Neither a reassuring sales page nor an alarming headline can decide whether a specific prescription is appropriate. That decision belongs with a licensed provider using current facts, with a licensed pharmacy responsible for dispensing.

Start when you are ready

See all treatments›

How care works

The Edit Health LLC provides management and administrative support. It does not practice medicine and is not a pharmacy. Licensed providers at Arora Health & Aesthetics, LLC, the affiliated medical practice, review health information and determine whether any treatment is appropriate. If medication is prescribed under the current care pathway, The Pharmacy Hub, a licensed U.S. pharmacy, handles dispensing, and care continues through secure follow-up. If you are not approved, you are not charged. No statement here confirms the availability, legality, or appropriateness of a particular compounded GLP-1 prescription as of a later date.

Frequently asked questions

Is compounded semaglutide FDA-approved?

No. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. The dispensing pharmacy may be licensed or registered under applicable rules, but that does not make the compounded product FDA-approved. [3]

Is compounded semaglutide generic Ozempic or Wegovy?

No. It should not be described as a generic, equivalent, or automatically interchangeable version of either brand. Compounded products are not affiliated with, endorsed by, or substitutes for Ozempic or Wegovy.

Can pharmacies still compound semaglutide or tirzepatide in 2026?

The answer depends on the compounding pathway, current federal and state rules, the drug’s status, the substance used, and the facts of an individual prescription. As of August 22, 2026, semaglutide and tirzepatide were not on FDA’s shortage list, and shortage-era blanket explanations were not sufficient. [1] Seek current legal and clinical guidance for a specific situation.

What are semaglutide salt forms?

Semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide used in FDA-approved drugs. FDA says it is unaware of a lawful basis for their use in compounding. [3]

How can I verify a compounding pharmacy?

Ask for its legal name, physical location, and whether it operates under 503A or as a registered 503B outsourcing facility. Check state board records and, when relevant, FDA’s outsourcing-facility information. Do not confuse licensing or registration with FDA approval of a compounded product.

Sources

1. FDA, compounding policy clarification, April 1, 2026: fda.gov policy clarification
2. FDA, proposed exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulks list, April 30, 2026: fda.gov announcement
3. FDA, concerns with unapproved GLP-1 drugs, updated through May 31, 2026: fda.gov GLP-1 concerns
4. FDA warning letter on misleading compounded GLP-1 marketing, June 8, 2026: fda.gov warning letter
5. Federal Register, extension of the 503B bulks-list proposal comment period through July 30, 2026, with FDA’s compounding policy index rechecked August 22, 2026: federalregister.gov notice fda.gov compounding policies